MC
TEVA icon

Moors & Cabot’s Teva Pharmaceuticals TEVA Stock Holding History

Moors & Cabot’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,630
Closed -$104K – 967
2021
Q3 		$104K Sell
10,630
-1,835
-15% -$17.2K 0.01% 797
2021
Q2 		$123K Sell
12,465
-3,615
-22% -$38.3K 0.01% 764
2021
Q1 		$188K Sell
16,080
-13,485
-46% -$155K 0.01% 694
2020
Q4 		$289K Sell
29,565
-5,970
-17% -$57.2K 0.02% 540
2020
Q3 		$320K Sell
35,535
-7,175
-17% -$75.9K 0.03% 454
2020
Q2 		$524K Buy
42,710
+4,105
+11% +$46.4K 0.06% 305
2020
Q1 		$343K Sell
38,605
-4,650
-11% -$47.6K 0.05% 334
2019
Q4 		$429K Buy
43,255
+20,873
+93% +$186K 0.04% 377
2019
Q3 		$152K Buy
22,382
+4,445
+25% +$34.1K 0.02% 568
2019
Q2 		$165K Sell
17,937
-1,963
-10% -$23.7K 0.02% 521
2019
Q1 		$316K Sell
19,900
-7,800
-28% -$138K 0.04% 374
2018
Q4 		$434K Sell
27,700
-21,102
-43% -$433K 0.07% 282
2018
Q3 		$1.05M Buy
48,802
+16,025
+49% +$372K 0.13% 184
2018
Q2 		$788K Buy
32,777
+15,870
+94% +$324K 0.11% 214
2018
Q1 		$289K Buy
16,907
+1,655
+11% +$32.3K 0.04% 439
2017
Q4 		$294K Sell
15,252
-7,353
-33% -$111K 0.04% 423
2017
Q3 		$404K Sell
22,605
-2,181
-9% -$49.1K 0.06% 348
2017
Q2 		$823K Sell
24,786
-1,343
-5% -$41.6K 0.14% 191
2017
Q1 		$833K Buy
26,129
+222
+0.9% +$7.58K 0.14% 188
2016
Q4 		$943K Buy
25,907
+6,146
+31% +$245K 0.16% 157
2016
Q3 		$917K Buy
19,761
+1,226
+7% +$64K 0.15% 160
2016
Q2 		$935K Buy
18,535
+1,013
+6% +$53.9K 0.16% 153
2016
Q1 		$939K Sell
17,522
-6,167
-26% -$362K 0.17% 155
2015
Q4 		$1.56M Sell
23,689
-1,054
-4% -$65.1K 0.29% 95
2015
Q3 		$1.4M Sell
24,743
-5,542
-18% -$359K 0.26% 102
2015
Q2 		$1.8M Sell
30,285
-589
-2% -$36.3K 0.29% 86
2015
Q1 		$1.92M Buy
30,874
+736
+2% +$42.8K 0.32% 85
2014
Q4 		$1.74M Sell
30,138
-841
-3% -$46.9K 0.29% 88
2014
Q3 		$1.66M Sell
30,979
-2,301
-7% -$122K 0.28% 91
2014
Q2 		$1.74M Buy
33,280
+13,161
+65% +$673K 0.29% 84
2014
Q1 		$1.06M Buy
+20,119
New +$930K 0.27% 100

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Moors & Cabot's TEVA Position: Q4 2021 in Review

Moors & Cabot sold out of Teva Pharmaceuticals (TEVA) in Q4 2021, closing a stake of 10,630 shares — an estimated $104K sold.

Moors & Cabot first reported a position in TEVA in Q1 2014 and held it in 31 quarters. The position peaked at $1.92M in Q1 2015. 450 funds tracked by Wall St. Rank hold TEVA as of Q4 2021.

  • Moors & Cabot reported no remaining Teva Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Moors & Cabot sold 10,630 Teva Pharmaceuticals shares in Q4 2021, an estimated $104K.
  • Moors & Cabot first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 31 quarters.
  • Moors & Cabot's Teva Pharmaceuticals position peaked at $1.92M in Q1 2015.
  • 450 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2021.

Based on Moors & Cabot's 13F filing for Q4 2021, filed 14 Feb 2022.